Bristol Myers (BMY) announces FDA approves Nivolumab with chemotherapy for previously untreated hodgkin lymphoma
Importance
Level 1
#BRISTOL-MYERS SQUIBB CO#BMY.US#FDA#EQUITIES#EU SESSION#US SESSION#PHARMACEUTICALS#PHARMACEUTICALS (GROUP)#PHARMACEUTICALS, BIOTECHNOLOGY & LIFE SCIENCES#S&P 500 INDEX#BMY#US EQUITIES